Social Anxiety

Neurology
0
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
3 programs
Imaginal RescriptingN/A1 trial
Imaginal exposure for memoriesN/A1 trial
Imaginal exposure one-sessionN/A1 trial
Active Trials
NCT03140839Completed33Est. Aug 2018
NCT05292807Unknown460Est. Jan 2025
NCT04635904Unknown100Est. Aug 2023
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
DSB-IN/A1 trial
Active Trials
NCT05996419Completed23Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Johnson & JohnsonDSB-I
Jerusalem PharmaceuticalsImaginal exposure for memories
Jerusalem PharmaceuticalsImaginal exposure one-session
Jerusalem PharmaceuticalsImaginal Rescripting

Clinical Trials (4)

Total enrollment: 616 patients across 4 trials

Intervention to Reduce Safety Behaviors

Start: Jul 2024Est. completion: Dec 202523 patients
N/ACompleted
NCT05292807Jerusalem PharmaceuticalsImaginal exposure for memories

Imagery Rescripting and Imaginal Exposure for Anxiety Symptoms

Start: Apr 2022Est. completion: Jan 2025460 patients
N/AUnknown
NCT04635904Jerusalem PharmaceuticalsImaginal exposure one-session

Imagery Rescripting and Imaginal Exposure for Social Anxiety: Mechanisms and Outcomes in an Analog Sample

Start: Apr 2021Est. completion: Aug 2023100 patients
N/AUnknown

Treating Negative Mental Images and Memories in Social Anxiety

Start: May 2017Est. completion: Aug 201833 patients
N/ACompleted

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space